JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $276

Benzinga Newsdesk www.benzinga.com Positive 87.8%

Neg 0% Neu 0% Pos 87.8%

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $265 to $276.